{"protocolSection": {"identificationModule": {"nctId": "NCT01763346", "orgStudyIdInfo": {"id": "BETAFAT"}, "secondaryIdInfos": [{"id": "U01DK094430", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U01DK094430"}, {"id": "IIT - 000395", "type": "OTHER_GRANT", "domain": "Allergan Corporation"}], "organization": {"fullName": "University of Southern California", "class": "OTHER"}, "briefTitle": "Beta Cell Restoration Through Fat Mitigation", "officialTitle": "Beta Cell Restoration Through Fat Mitigation", "acronym": "BetaFat"}, "statusModule": {"statusVerifiedDate": "2019-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-06"}, "primaryCompletionDateStruct": {"date": "2018-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-01-04", "studyFirstSubmitQcDate": "2013-01-07", "studyFirstPostDateStruct": {"date": "2013-01-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-08-28", "resultsFirstSubmitQcDate": "2019-10-15", "resultsFirstPostDateStruct": {"date": "2019-10-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-10-15", "lastUpdatePostDateStruct": {"date": "2019-10-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Thomas Buchanan", "investigatorTitle": "Professor", "investigatorAffiliation": "University of Southern California"}, "leadSponsor": {"name": "University of Southern California", "class": "OTHER"}, "collaborators": [{"name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Weight loss achieved through gastric banding will be superior to treatment with metformin in preserving or restoring pancreatic beta cell function in people with prediabetes or mild type 2 diabetes.", "detailedDescription": "BetaFat is a 2-arm, unblinded study to compare gastric banding to treatment with metformin over a 24-month period in moderately obese adults with pre- or mild type 2 diabetes. The primary outcome will be change in \u03b2-cell compensation for insulin resistance, which the investigators will compare between groups. Secondary analyses will include other potential markers of \u03b2-cell health and potential mediators of treatment-specific effects. The main focus will be on mediators related to obesity. Clinically, the project will serve as a test of concept for use of gastric banding relatively early in the spectrum of obesity and \u03b2-cell disease. Biologically, the results will provide crucial information on potential mediators of \u03b2-cell failure and its arrest or reversal in the context of obesity. Those mediators will guide the development of more effective treatment and monitoring for the \u03b2-cell disease that causes type 2 diabetes."}, "conditionsModule": {"conditions": ["Prediabetes", "Type 2 Diabetes", "Obesity"], "keywords": ["type 2 diabetes", "prediabetes", "obesity", "gastric banding", "metformin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 88, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "metformin", "type": "ACTIVE_COMPARATOR", "description": "subjects receiving metformin", "interventionNames": ["Drug: Metformin"]}, {"label": "gastric banding", "type": "EXPERIMENTAL", "description": "subjects receiving LAP-BAND", "interventionNames": ["Device: gastric banding"]}], "interventions": [{"type": "DRUG", "name": "Metformin", "description": "metformin 1000 mg bid", "armGroupLabels": ["metformin"]}, {"type": "DEVICE", "name": "gastric banding", "description": "LAP-BAND", "armGroupLabels": ["gastric banding"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Steady State Beta Cell Compensation", "description": "mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity", "timeFrame": "24 months"}], "otherOutcomes": [{"measure": "Glycemia", "description": "fasting and 2-hour OGTT glucose levels", "timeFrame": "24 months"}, {"measure": "Glycemia", "description": "HbA1C", "timeFrame": "24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Prior completion of at least two months in a diet, exercise and lifestyle intervention program within the past two years\n2. Fasting plasma glucose \\>90 mg/dl plus 2-hour glucose \u2265140 mg/dl on 75 gm OGTT plus HbA1C \u22647.0%. There is no lower limit for the A1C and no upper limit for the OGTT 2-hour glucose based on prior studies that allow us to identify people with falling \u03b2-cell function\n3. Age 22-65 years\n4. Body mass index (BMI) 30-40 kg/m2\n5. For participants with diabetes, known duration \\<1 year\n6. No history of use of antidiabetic medications except during pregnancy\n\nExclusion Criteria:\n\n1. Contraindications to LapBand(see Appendix 1)\n2. Contraindication to MRI (claustrophobia; permanent metal objects such as pacemakers, prostheses, aneurysm clips)\n3. Underlying disease(s) likely to (a) limit life span to less than study duration and/or (b) increase risk of intervention outside of the study and/or (c) limit ability to participate in outcomes assessment and/or (d) limit participation\n4. An underlying disease known to have important effects on glucose metabolism\n5. Active infections\n6. Renal disease (serum creatinine \u22651.4 mg/dl for men; \u22651.3 mg/dl for women) or serum potassium abnormality (\\<3.4 or \\>5.5 mmol/l)\n7. Anemia (hemoglobin \\<11g/dl in women, \\<12 g/dl in men) or known coagulopathy\n8. Cardiovascular disease, including uncontrolled hypertension and symptomatic congestive heart failure. Participants must be able to safely tolerate administration of fluid/volume challenges during clamp studies.\n9. Serum AST \\>3 times upper limit of normal in local clinical lab\n10. Excessive alcohol intake\n11. Suboptimally treated thyroid disease\n12. Conditions or behaviors likely to affect the conduct of the study\n\n    1. unable or unwilling to give informed consent\n    2. unable to adequately communicate with clinic staff\n    3. another household member is a participant or staff member\n    4. current or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes\n    5. likely to move away from participating clinic in next 2 years\n    6. current (or anticipated) pregnancy and lactation.\n    7. major psychiatric disorder that, in the opinion of clinic staff, would impede the conduct of the study\n    8. weight loss \\>5% in past three months for any reason except postpartum weight loss.\n13. additional conditions may serve as criteria for exclusion at the discretion of the local site", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "22 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Thomas A Buchanan, MD", "affiliation": "University of Southern California", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Southern California", "city": "Los Angeles", "state": "California", "zip": "91011", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}]}, "referencesModule": {"references": [{"pmid": "24194506", "type": "BACKGROUND", "citation": "RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of beta-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014;37(3):780-8. doi: 10.2337/dc13-1879. Epub 2013 Nov 5."}, {"pmid": "30282699", "type": "RESULT", "citation": "Xiang AH, Trigo E, Martinez M, Katkhouda N, Beale E, Wang X, Wu J, Chow T, Montgomery C, Nayak KS, Hendee F, Buchanan TA; RISE Consortium; RISE Collaborators. Impact of Gastric Banding Versus Metformin on beta-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care. 2018 Dec;41(12):2544-2551. doi: 10.2337/dc18-1662. Epub 2018 Oct 3."}, {"pmid": "29941497", "type": "RESULT", "citation": "RISE Consortium. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care. 2018 Aug;41(8):1696-1706. doi: 10.2337/dc18-0244. Epub 2018 Jun 25."}, {"pmid": "35894078", "type": "DERIVED", "citation": "Utzschneider KM, Ehrmann DA, Arslanian SA, Barengolts E, Buchanan TA, Caprio S, Edelstein SL, Hannon TS, Kahn SE, Kozedub A, Mather KJ, Nadeau KJ, Sam S, Tripputi M, Xiang AH, El Ghormli L; RISE Consortium. Weight loss and beta-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. Obesity (Silver Spring). 2022 Aug;30(8):1579-1588. doi: 10.1002/oby.23475."}, {"pmid": "34135015", "type": "DERIVED", "citation": "Kahn SE, Edelstein SL, Arslanian SA, Barengolts E, Caprio S, Ehrmann DA, Hannon TS, Marcovina S, Mather KJ, Nadeau KJ, Utzschneider KM, Xiang AH, Buchanan TA; RISE Consortium; Rise Consortium Investigators:. Effect of Medical and Surgical Interventions on alpha-Cell Function in Dysglycemic Youth and Adults in the RISE Study. Diabetes Care. 2021 Sep;44(9):1948-1960. doi: 10.2337/dc21-0461. Epub 2021 Jun 16."}, {"pmid": "34131047", "type": "DERIVED", "citation": "Kahn SE, Mather KJ, Arslanian SA, Barengolts E, Buchanan TA, Caprio S, Ehrmann DA, Hannon TS, Marcovina S, Nadeau KJ, Utzschneider KM, Xiang AH, Edelstein SL; RISE Consortium; Rise Consortium Investigators:. Hyperglucagonemia Does Not Explain the beta-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care. 2021 Sep;44(9):1961-1969. doi: 10.2337/dc21-0460. Epub 2021 Jun 15."}, {"pmid": "33436401", "type": "DERIVED", "citation": "Arslanian SA, El Ghormli L, Kim JY, Tjaden AH, Barengolts E, Caprio S, Hannon TS, Mather KJ, Nadeau KJ, Utzschneider KM, Kahn SE; RISE Consortium. OGTT Glucose Response Curves, Insulin Sensitivity, and beta-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve beta-Cell Function. Diabetes Care. 2021 Mar;44(3):817-825. doi: 10.2337/dc20-2134. Epub 2021 Jan 12."}, {"pmid": "31301210", "type": "DERIVED", "citation": "RISE Consortium. Obesity and insulin sensitivity effects on cardiovascular risk factors: Comparisons of obese dysglycemic youth and adults. Pediatr Diabetes. 2019 Nov;20(7):849-860. doi: 10.1111/pedi.12883. Epub 2019 Jul 29."}, {"pmid": "29941498", "type": "DERIVED", "citation": "RISE Consortium. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test. Diabetes Care. 2018 Aug;41(8):1707-1716. doi: 10.2337/dc18-0243. Epub 2018 Jun 25."}, {"pmid": "28493515", "type": "DERIVED", "citation": "Hannon TS, Kahn SE, Utzschneider KM, Buchanan TA, Nadeau KJ, Zeitler PS, Ehrmann DA, Arslanian SA, Caprio S, Edelstein SL, Savage PJ, Mather KJ; RISE Consortium. Review of methods for measuring beta-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium. Diabetes Obes Metab. 2018 Jan;20(1):14-24. doi: 10.1111/dom.13005. Epub 2017 Jun 22."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Five participants randomized to metformin and six participants randomized to gastric banding refused to initiate treatment", "recruitmentDetails": "Recruited from Kaiser Permanente Southern California", "groups": [{"id": "FG000", "title": "Metformin", "description": "subjects receiving metformin\n\nMetformin: metformin 1000 mg bid"}, {"id": "FG001", "title": "Gastric Banding", "description": "subjects receiving LAP-BAND\n\ngastric banding: LAP-BAND"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Five subjects who enrolled in the study refused to initiate metformin therapy, thus did not \"start\"", "numSubjects": "44"}, {"groupId": "FG001", "comment": "Six subjects randomized to gastric banding refused the banding surgery and, thus, did not \"start\"", "numSubjects": "44"}]}, {"type": "Received Intervention", "achievements": [{"groupId": "FG000", "numSubjects": "39"}, {"groupId": "FG001", "numSubjects": "38"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "36"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Metformin", "description": "subjects receiving metformin\n\nMetformin: metformin 1000 mg bid"}, {"id": "BG001", "title": "Gastric Banding", "description": "subjects receiving LAP-BAND\n\ngastric banding: LAP-BAND"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "88"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "88"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "69"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "19"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "40"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "48"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "16"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "65"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "88"}]}]}]}, {"title": "Hyperglycemic clamp", "description": "data are reported as gemetric mean and 95% confidence interval", "paramType": "GEOMETRIC_MEAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "nmol/l adjusted for insulin sensitivity", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.37", "lowerLimit": "2.71", "upperLimit": "3.35"}, {"groupId": "BG001", "value": "3.67", "lowerLimit": "3.28", "upperLimit": "4.1"}, {"groupId": "BG002", "value": "3.52", "lowerLimit": "2.99", "upperLimit": "3.74"}]}]}]}, {"title": "Oral Glucose Tolerance Test", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/l", "classes": [{"title": "fasting glucose", "categories": [{"measurements": [{"groupId": "BG000", "value": "6.2", "spread": "0.8"}, {"groupId": "BG001", "value": "6.2", "spread": "0.7"}, {"groupId": "BG002", "value": "6.2", "spread": "0.75"}]}]}, {"title": "2-hour glucose", "categories": [{"measurements": [{"groupId": "BG000", "value": "10.5", "spread": "2.6"}, {"groupId": "BG001", "value": "10.4", "spread": "2.7"}, {"groupId": "BG002", "value": "10.45", "spread": "2.65"}]}]}]}, {"title": "Body weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilograms", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "96.1", "spread": "10.9"}, {"groupId": "BG001", "value": "97.5", "spread": "12.2"}, {"groupId": "BG002", "value": "96.8", "spread": "11.8"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilograms per meters squared", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35.0", "spread": "2.9"}, {"groupId": "BG001", "value": "35.7", "spread": "2.9"}, {"groupId": "BG002", "value": "35.53", "spread": "2.9"}]}]}]}, {"title": "Hemoglobin A1C", "description": "values are given as standard error and not standard deviation", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent of hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.82", "spread": "0.06"}, {"groupId": "BG001", "value": "5.92", "spread": "0.06"}, {"groupId": "BG002", "value": "5.87", "spread": "0.06"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Steady State Beta Cell Compensation", "description": "mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity", "populationDescription": "Participants completing 24-month hyperglycemic clamp", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "(nmol/L) adjusted for M/I", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Metformin", "description": "subjects receiving metformin\n\nMetformin: metformin 1000 mg bid"}, {"id": "OG001", "title": "Gastric Banding", "description": "subjects receiving LAP-BAND\n\ngastric banding: LAP-BAND"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.01", "lowerLimit": "2.71", "upperLimit": "3.35"}, {"groupId": "OG001", "value": "3.19", "lowerLimit": "2.88", "upperLimit": "3.53"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "We selected a sample size that would allow detection of an effect size of \\~0.6 or greater between gastric band and metformin groups for measures of \u03b2-cell function after two years, hypothesizing greater function in the gastric band group.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.05", "pValueComment": "35 subjects per group provided 80% power to detect an effect size of 0.59, assuming a 2-sided p=0.05, adjustment for baseline measures using ANCOVA, and correlation of 0.5 between baseline and end-study measures.", "statisticalMethod": "General Linear Models", "statisticalComment": "Differences in primary outcomes between groups at 24-months were compared using general linear models with baseline values included as covariates."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Glycemia", "description": "fasting and 2-hour OGTT glucose levels", "populationDescription": "participants completing 24 months of interventions", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/l", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Metformin", "description": "subjects receiving metformin\n\nMetformin: metformin 1000 mg bid"}, {"id": "OG001", "title": "Gastric Banding", "description": "subjects receiving LAP-BAND\n\ngastric banding: LAP-BAND"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "36"}]}], "classes": [{"title": "fasting glucose", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.95", "spread": "0.11"}, {"groupId": "OG001", "value": "5.85", "spread": "0.18"}]}]}, {"title": "2-hour glucose", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.87", "spread": "0.57"}, {"groupId": "OG001", "value": "9.92", "spread": "0.54"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Glycemia", "description": "HbA1C", "populationDescription": "participants completing 24 months of interventions", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent of hemoglobin", "timeFrame": "24 months", "groups": [{"id": "OG000", "title": "Metformin", "description": "subjects receiving metformin\n\nMetformin: metformin 1000 mg bid"}, {"id": "OG001", "title": "Gastric Banding", "description": "subjects receiving LAP-BAND\n\ngastric banding: LAP-BAND"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.84", "spread": "0.09"}, {"groupId": "OG001", "value": "5.73", "spread": "0.09"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "24 months", "eventGroups": [{"id": "EG000", "title": "Metformin", "description": "subjects receiving metformin\n\nMetformin: metformin 1000 mg bid", "deathsNumAffected": 0, "deathsNumAtRisk": 39, "seriousNumAffected": 2, "seriousNumAtRisk": 39, "otherNumAffected": 18, "otherNumAtRisk": 39}, {"id": "EG001", "title": "Gastric Banding", "description": "subjects receiving LAP-BAND\n\ngastric banding: LAP-BAND", "deathsNumAffected": 0, "deathsNumAtRisk": 38, "seriousNumAffected": 4, "seriousNumAtRisk": 38, "otherNumAffected": 3, "otherNumAtRisk": 38}], "seriousEvents": [{"term": "gastric band slippage requiring removal", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "gastric band slippage requireing removal", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}]}, {"term": "breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}]}, {"term": "acalcuous cholecystitis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Requering gall bladder removal", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "Ankle fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "requiring fixation, resutling from traffic accident", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Gastric sleeve surgery", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "elective", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}], "otherEvents": [{"term": "Port revision", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 38}]}, {"term": "dysphagia", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 38}]}, {"term": "stomach pain or discomfort", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "dairrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "heartburn", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}, {"term": "Lack of energy", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 38}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Thomas Buchanan", "organization": "University or Southern California", "email": "buchanan@usc.edu", "phone": "3234794319"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-08-28", "uploadDate": "2019-08-28T18:43", "filename": "Prot_SAP_000.pdf", "size": 1501815}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2018-04-05", "uploadDate": "2019-08-28T18:54", "filename": "ICF_001.pdf", "size": 467559}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}, {"id": "D000011236", "term": "Prediabetic State"}, {"id": "D000018149", "term": "Glucose Intolerance"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000006943", "term": "Hyperglycemia"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M14117", "name": "Prediabetic State", "asFound": "Prediabetes", "relevance": "HIGH"}, {"id": "M12701", "name": "Obesity", "relevance": "LOW"}, {"id": "M20295", "name": "Glucose Intolerance", "asFound": "Prediabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M9994", "name": "Hyperglycemia", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}